ストックスクリーナーアプリを入手
23.88
6.76%
-1.73
アフターアワーズ：
24.01
0.13
+0.54%
前日終値:
$25.61
開ける：
$25.08
24時間の取引高:
408.24K
Relative Volume:
0.73
時価総額：
$752.80M
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-14.35%
1か月 パフォーマンス:
+29.22%
6か月 パフォーマンス:
+0.00%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$23.88
$25.73
1週間の範囲:
$23.88
$30.05
52週間の値動き範囲:
$13.88
$33.20
Evommune Inc Stock (EVMN) Company Profile
Compare EVMN vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
EVMN
Evommune Inc
|
23.88 | 807.33M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.27 | 123.47B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
766.66 | 83.60B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
748.72 | 46.83B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
318.65 | 43.11B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
297.04 | 34.79B | 5.36B | 287.73M | 924.18M | 2.5229 |
Evommune Inc Stock (EVMN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-22 | 開始されました | Oppenheimer | Outperform |
| 2026-01-08 | 開始されました | Raymond James | Strong Buy |
| 2026-01-06 | 開始されました | H.C. Wainwright | Buy |
| 2025-12-01 | 開始されました | Cantor Fitzgerald | Overweight |
| 2025-12-01 | 開始されました | Evercore ISI | Outperform |
| 2025-12-01 | 開始されました | Leerink Partners | Outperform |
| 2025-12-01 | 開始されました | Morgan Stanley | Overweight |
| 2025-12-01 | 開始されました | William Blair | Outperform |
すべてを表示
Evommune Inc (EVMN) 最新ニュース
Evommune (EVMN) Insider Trading Activity 2026 - MarketBeat
EVMN Technical Analysis & Stock Price Forecast - Intellectia AI
Evommune (NYSE:EVMN) Trading Down 10.2%Time to Sell? - MarketBeat
Evommune (EVMN) Price Target Increased by 37.87% to 55.08 - Nasdaq
Evommune CEO Luis Peña Reveals What’s Behind Company’s Post-IPO Success - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: Evommune, Inc. (EVMN) and Charles River Labs (CRL) - The Globe and Mail
Evommune (NYSE:EVMN) Trading Down 7.4%Time to Sell? - MarketBeat
Morgan Stanley Maintains Overweight on Evommune (EVMN) Feb 18 2026 - Meyka
Eczema Pipeline 2026 Outlook: 100+ Clinical Assets and 3 Key Late-Stage Candidates to Watch, analyses DelveInsight - openPR.com
This Biotech Stock Nearly Doubled In Value Today Morning – What’s Driving Investor Optimism? - MSN
Evommune announces $125 million private placement - The Pharma Letter
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet - Finviz
Benzinga Stock Whisper Index Analysis - Intellectia AI
Evommune, Inc. Common Stock (NYSE:EVMN) Stock Quote - FinancialContent
Evommune raises $125 million in private placement to fund R&D By Investing.com - Investing.com Canada
Assessing Evommune (EVMN) Valuation After Strong Phase 2a Eczema Data And US$125.3m Placement - Yahoo Finance
Evommune, Inc. (NYSE:EVMN) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Evommune (NYSE:EVMN) Shares Gap UpHere's Why - MarketBeat
Weekly Buzz:FDA Okays NVCR's Cancer Device; RGNX Gets CRL;ONCO To Buy XBOT; PHIO's PH-762 Sets Pace - RTTNews
Evommune Inc on Feb 12, enters securities purchase agreement with investors - marketscreener.com
Evommune Announces $125 Million Private Placement Financing - TipRanks
Evommune Inc On Feb 12, Enters Securities Purchase Agreement With Investors - TradingView
Evommune Signs Multiple Material Agreements - TradingView
Evommune raises $125M privately - MSN
Evommune raises $125 million in private placement to fund R&D - Investing.com Australia
Evommune to Raise $125 Million Via Private Placement - marketscreener.com
Evommune's stock surges on strong results for new eczema drug - MSN
Evommune Secures $125M in Private Placement Agreement - Intellectia AI
Evommune’s atopic dermatitis drug meets primary endpoint in phase 2a trial - Investing.com Nigeria
Evommune Enters Private Placement Agreement for $125 Million - Intellectia AI
Evommune Announces $125 Million Private Placement - Business Wire
Evommune Inc (EVMN-N) Insider Trade Summaries - The Globe and Mail
Evommune Stock Cools Off After Big Rally On Successful Eczema Trial - Bitget
Evommune (EVMN) Valuation Check After Positive Phase 2a EVO301 Results In Atopic Dermatitis - simplywall.st
Evommune rockets on eczema data; AstraZeneca advances GLP-1 pill - BioPharma Dive
Evommune's EVO301 Phase 2a Data Drives 70% Stock Surge (NYSE:EVMN) - Seeking Alpha
Evommune’s stock rallies 70% on Phase IIa eczema data - Yahoo Finance
Biopharma companies Evommune and Nektar soar on eczema treatment data - Mugglehead Investment Magazine
Evommune stock price slips premarket after 71% jump on eczema drug data - Bez Kabli
Evommune’s atopic dermatitis drug meets primary endpoint in phase 2a trial By Investing.com - Investing.com South Africa
Evommune stock soars after positive Phase 2a trial results for eczema drug - Investing.com
Evommune soars on mid-stage atopic dermatitis data - FirstWord Pharma
Evommune, Nektar assets join list of recent successes in atopic derm - BioCentury
H.C. Wainwright maintains Buy for EVMN Evommune Inc Feb 10 2026 - Meyka
Evommune, Nektar soar on atopic dermatitis phase II data - BioWorld MedTech
Evommune’s Atopic Dermatitis Data Competitive With Dupixent - Citeline News & Insights
Evommune Inc (EVMN) 財務データ
Evommune Inc (EVMN) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
5.71%
0.02%
大文字化:
|
ボリューム (24 時間):